OXURION to Participate in Upcoming Investor Meetings
THR-149 has shown positive topline Phase 1 results for the treatment of DME.
- THR-149 has shown positive topline Phase 1 results for the treatment of DME.
- The Company is currently conducting a Phase 2 clinical trial evaluating multiple injections of THR-149 with DME-patients who previously responded sub-optimally to anti-VEGF therapy.
- Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.
- This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction.